Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Reviewing Chantix Postmarketing Data On Suicide, Erratic Behavior

This article was originally published in The Pink Sheet Daily

Executive Summary

Early communication by the agency follows one case of erratic behavior leading to the death of a patient using the smoking cessation drug.

You may also be interested in...

Pfizer's Pitch For Chantix Warning Reduction Focuses On Those With Mental Illness

Those patients need more options for smoking cessation, Pfizer says, but that is the group FDA most worries about when deciding whether to remove its boxed warning.

Pfizer's Chantix Warning May Remain As FDA Raises Trial Concerns

FDA will present concerns on data collection and study conduct during advisory committee meeting on removing smoking cessation drug's boxed warning.

FDA’s Black Box Instant Replay: A Higher Standard To Remove

Pfizer’s request for leniency on Chantix will likely be shelved, but advisory committee allows exploration of regulatory area where FDA has limited experience: The rollback of safety labeling.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts